WEBCAST Integrated Myeloma Management of Transplant-Eligible Patients
The Conjunction of Novel Therapeutic Platforms, Innovative Agents, and HCT
This PeerView activity, based on a recent live symposium held at the 2018 BMT Tandem Meetings, offers expert insights on the continued integration of next-generation and novel therapeutics in conjunction with the use of autologous hematopoietic stem cell transplant (HCT), while also exploring the clinical implications of new data for the selection of newer induction, post-HCT maintenance, and salvage regimens across the breadth of myeloma treatment settings. Our panel of myeloma experts also assess other issues in transplant-eligible myeloma patients, including early versus late HCT, the growing importance of minimal residual disease (MRD) assessment, and the emergence of new agent classes and therapeutic concepts for heavily pretreated individuals, including those who have had HCT as part of their treatment history.
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the management of patients with multiple myeloma.
Upon completion of this activity, participants should be better able to:
- Summarize evidence regarding the current role and clinical criteria for the use of emerging and established regimens in conjunction with autologous stem cell transplantation (ASCT) in the management of multiple myeloma
- Develop personalized induction and post–ASCT maintenance/consolidation regimens with novel components for eligible patients with multiple myeloma
- Select novel therapeutics for the management of relapsed multiple myeloma post-ASCT
Planning Director: Mary Horowitz
No one in control of content has any relevant financial relationships to disclose.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by independent medical educational grants from Astellas, Merck & Co., Inc., and Shire. This session is open to all registrants of the 2018 BMT Tandem Meetings.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.